Literature DB >> 20089795

Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection.

Adriana T Moreno1, Maria Leonor S Oliveira, Daniela M Ferreira, Paulo L Ho, Michelle Darrieux, Luciana C C Leite, Jorge M C Ferreira, Fabiana C Pimenta, Ana Lúcia S S Andrade, Eliane N Miyaji.   

Abstract

PspA is an important candidate for a vaccine with serotype-independent immunity against pneumococcal infections. Based on sequence relatedness, PspA has been classified into three families comprising six clades. We have previously addressed the cross-reactivity of antibodies against PspA fragments containing the N-terminal and proline-rich regions of PspA from clades 1 to 5 (PspA1, PspA2, PspA3, PspA4, and PspA5) by Western blot analysis and reported that anti-PspA4 and anti-PspA5 were able to recognize pneumococci expressing PspA proteins from all of the clades analyzed. We have now analyzed the functional capacity of these antibodies to bind and to mediate complement deposition on intact bacteria in vitro. Our results show that both PspA4 and PspA5 elicit antibodies that are able to bind and to mediate complement deposition efficiently on pneumococcal strains bearing PspA proteins from clades 1 to 5. Moreover, mice immunized with PspA4 and PspA5 were protected against an intranasal lethal challenge with strains expressing PspA proteins from the two major families. PspA4 and PspA5 are thus able to induce antibodies with a high degree of cross-reactivity in vitro, which is reflected in cross-protection of mice. We have also analyzed the contribution of the nonproline (NonPro) block within the conserved proline-rich region to the reactivity of anti-PspA antibodies, and the results indicate that N-terminal alpha-helical region, the blocks of proline repeats, and the NonPro region can influence the degree of cross-reactivity of antibodies to PspA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20089795      PMCID: PMC2837969          DOI: 10.1128/CVI.00430-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  28 in total

1.  Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae.

Authors:  A H Tu; R L Fulgham; M A McCrory; D E Briles; A J Szalai
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

Review 3.  Streptococcus pneumoniae protein vaccine candidates: properties, activities and animal studies.

Authors:  Stanley S Tai
Journal:  Crit Rev Microbiol       Date:  2006       Impact factor: 7.624

4.  PspA family typing and PCR-based DNA fingerprinting with BOX A1R primer of pneumococci from the blood of patients in the USA with and without sickle cell disease.

Authors:  D B Payne; A Sun; J C Butler; S P Singh; S K Hollingshead; D E Briles
Journal:  Epidemiol Infect       Date:  2005-02       Impact factor: 2.451

5.  Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004.

Authors:  Susan S Huang; Richard Platt; Sheryl L Rifas-Shiman; Stephen I Pelton; Donald Goldmann; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2005-09       Impact factor: 7.124

6.  Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules.

Authors:  G S Nabors; P A Braun; D J Herrmann; M L Heise; D J Pyle; S Gravenstein; M Schilling; L M Ferguson; S K Hollingshead; D E Briles; R S Becker
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

7.  Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae.

Authors:  A D Ogunniyi; R L Folland; D E Briles; S K Hollingshead; J C Paton
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

8.  Effect of the seven-valent conjugate pneumococcal vaccine on carriage and drug resistance of Streptococcus pneumoniae in healthy children attending day-care centers in Lisbon.

Authors:  Nelson Frazão; António Brito-Avô; Carla Simas; Joana Saldanha; Rosario Mato; Sónia Nunes; Natacha G Sousa; João A Carriço; Jonas S Almeida; Ilda Santos-Sanches; Hermínia de Lencastre
Journal:  Pediatr Infect Dis J       Date:  2005-03       Impact factor: 2.129

9.  PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.

Authors:  Wei Xin; Yuhua Li; Hua Mo; Kenneth L Roland; Roy Curtiss
Journal:  Infect Immun       Date:  2009-08-17       Impact factor: 3.441

10.  The pspC gene of Streptococcus pneumoniae encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteremia.

Authors:  A Brooks-Walter; D E Briles; S K Hollingshead
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

View more
  36 in total

1.  Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.

Authors:  Míriam A da Silva; Thiago R Converso; Viviane M Gonçalves; Luciana C C Leite; Martha M Tanizaki; Giovana C Barazzone
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

2.  PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine.

Authors:  Christina M Croney; Mamie T Coats; Moon H Nahm; David E Briles; Marilyn J Crain
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

3.  Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.

Authors:  Kirsten Kuipers; Wouter S P Jong; Christa E van der Gaast-de Jongh; Diane Houben; Fred van Opzeeland; Elles Simonetti; Saskia van Selm; Ronald de Groot; Marije I Koenders; Taj Azarian; Elder Pupo; Peter van der Ley; Jeroen D Langereis; Aldert Zomer; Joen Luirink; Marien I de Jonge
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

Review 4.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

5.  Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.

Authors:  Constantine Bitsaktsis; Bibiana V Iglesias; Ying Li; Jesus Colino; Clifford M Snapper; Susan K Hollingshead; Giang Pham; Diane R Gosselin; Edmund J Gosselin
Journal:  Infect Immun       Date:  2011-12-12       Impact factor: 3.441

6.  Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.

Authors:  Eliane N Miyaji; Cintia F M Vadesilho; Maria Leonor S Oliveira; André Zelanis; David E Briles; Paulo L Ho
Journal:  Clin Vaccine Immunol       Date:  2014-12-17

7.  Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.

Authors:  Xiaorui Chen; Bo Li; Jinfei Yu; Yue Zhang; Zujian Mo; Tiejun Gu; Wei Kong; Yong Zhang; Yongge Wu
Journal:  Med Microbiol Immunol       Date:  2019-02-01       Impact factor: 3.402

8.  Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.

Authors:  Carolina Salcedo-Rivillas; Anne-Sophie Debrie; Eliane Namie Miyaji; Jorge M C Ferreira; Isaías Raw; Camille Locht; Paulo L Ho; Nathalie Mielcarek; Maria Leonor S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

9.  Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice.

Authors:  Maria Leonor S Oliveira; Eliane N Miyaji; Daniela M Ferreira; Adriana T Moreno; Patricia C D Ferreira; Fernanda A Lima; Fernanda L Santos; Maria Aparecida Sakauchi; Célia S Takata; Hisako G Higashi; Isaías Raw; Flavia S Kubrusly; Paulo L Ho
Journal:  PLoS One       Date:  2010-05-27       Impact factor: 3.240

10.  Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.

Authors:  Shannon L Haughney; Latrisha K Petersen; Amy D Schoofs; Amanda E Ramer-Tait; Janice D King; David E Briles; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2013-06-14       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.